Cytokinetics, Incorporated (CYTK)
CYTK Stock Price Chart
Explore Cytokinetics, Incorporated interactive price chart. Choose custom timeframes to analyze CYTK price movements and trends.
CYTK Company Profile
Discover essential business fundamentals and corporate details for Cytokinetics, Incorporated (CYTK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Apr 2004
Employees
673.00
Website
https://www.cytokinetics.comCEO
Robert I. Blum
Description
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Financial Timeline
Browse a chronological timeline of Cytokinetics, Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.64, while revenue estimate is $17.44m.
Earnings released on 5 May 2026
EPS came in at -$1.67 matching the estimated -$1.67, while revenue for the quarter reached $19.36m , beating expectations by +127.21%.
Earnings released on 24 Feb 2026
EPS came in at -$1.50 falling short of the estimated -$1.48 by -1.35%, while revenue for the quarter reached $17.76m , beating expectations by +156.34%.
Earnings released on 5 Nov 2025
EPS came in at -$1.54 surpassing the estimated -$1.59 by +3.14%, while revenue for the quarter reached $1.94m , missing expectations by -75.87%.
Earnings released on 7 Aug 2025
EPS came in at -$1.12 surpassing the estimated -$1.34 by +16.42%, while revenue for the quarter reached $66.77m , beating expectations by +3.13k%.
Earnings released on 6 May 2025
EPS came in at -$1.36 surpassing the estimated -$1.41 by +3.55%, while revenue for the quarter reached $1.58m , missing expectations by -43.36%.
Earnings released on 27 Feb 2025
EPS came in at -$1.26 surpassing the estimated -$1.29 by +2.33%, while revenue for the quarter reached $16.93m , beating expectations by +18.69%.
Earnings released on 6 Nov 2024
EPS came in at -$1.36 falling short of the estimated -$1.27 by -7.09%, while revenue for the quarter reached $463.00k , missing expectations by -77.41%.
Earnings released on 8 Aug 2024
EPS came in at -$1.31 falling short of the estimated -$1.02 by -28.43%, while revenue for the quarter reached $249.00k , missing expectations by -72.93%.
Earnings released on 8 May 2024
EPS came in at -$1.33 falling short of the estimated -$1.16 by -14.66%, while revenue for the quarter reached $835.00k , missing expectations by -7.22%.
Earnings released on 27 Feb 2024
EPS came in at -$1.38 falling short of the estimated -$1.03 by -33.98%, while revenue for the quarter reached $1.67m , missing expectations by -84.48%.
Earnings released on 2 Nov 2023
EPS came in at -$1.35 falling short of the estimated -$0.72 by -87.50%, while revenue for the quarter reached $378.00k , missing expectations by -96.59%.
Earnings released on 3 Aug 2023
EPS came in at -$1.34 falling short of the estimated -$1.23 by -8.94%, while revenue for the quarter reached $867.00k , missing expectations by -85.05%.
Earnings released on 4 May 2023
EPS came in at -$1.38 falling short of the estimated -$1.24 by -11.29%, while revenue for the quarter reached $4.61m , beating expectations by +120.72%.
Earnings released on 1 Mar 2023
EPS came in at -$1.45 falling short of the estimated -$1.22 by -18.85%, while revenue for the quarter reached $1.96m , missing expectations by -72.44%.
Earnings released on 3 Nov 2022
EPS came in at -$1.28 falling short of the estimated -$1.19 by -7.56%, while revenue for the quarter reached $2.52m , missing expectations by -28.29%.
Earnings released on 4 Aug 2022
EPS came in at -$0.23 surpassing the estimated -$1.04 by +77.88%, while revenue for the quarter reached $88.97m , beating expectations by +2.28k%.
Earnings released on 4 May 2022
EPS came in at -$1.02 falling short of the estimated -$0.93 by -9.68%, while revenue for the quarter reached $1.15m , missing expectations by -73.58%.
Earnings released on 24 Feb 2022
EPS came in at -$0.36 surpassing the estimated -$0.89 by +59.55%, while revenue for the quarter reached $55.60m , beating expectations by +858.41%.
Earnings released on 3 Nov 2021
EPS came in at -$0.95 falling short of the estimated -$0.75 by -26.67%, while revenue for the quarter reached $5.44m , missing expectations by -18.36%.
Earnings released on 5 Aug 2021
EPS came in at -$0.86 falling short of the estimated -$0.65 by -32.31%, while revenue for the quarter reached $2.84m , meeting expectations.
CYTK Stock Performance
Access detailed CYTK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
